Accessibility Menu
Uscom logo

Uscom(ASX) UCM

Market CapA$3.12MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2003)-99%
5 Year-93%
1 Year-14%
1 Month+9%
A$0.01
+0.00%
+0.00Today
Uscom last closing stock price
MetricPriceDate
Last closeAUD 0.012025-09-23
Uscom stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+9.09%AUD 0.012025-09-10
1 month+9.09%AUD 0.012025-08-08
3 month-36.84%AUD 0.022025-06-25
Year to date-62.5%AUD 0.032024-11-26
1 year-14.29%AUD 0.012024-09-19
3 year-84.62%AUD 0.082022-09-23
5 year-92.94%AUD 0.172020-09-24
Since inception-99.49%AUD 2.382003-12-10

Uscom Financials at a Glance

Market Cap

A$3.12MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

A$4.85M

Net Income (TTM)

-A$3.66M

EPS (TTM)

-A$0.01

P/E Ratio

-2.26

Dividend

A$0.00

Beta (Volatility)

0.15 (Low)

Price

A$0.01

Volume

0

Open

A$0.01

Previous Close

A$0.01

Daily Range

A$0.01 - A$0.01

52-Week Range

A$0.01 - A$0.01

Estimated Earnings Date

Feb 25, 2026

UCM News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Uscom

Uscom Limited specializes in the creation, production, and distribution of non-intrusive medical instruments for assessing heart and lung health. The company offers innovative solutions that enhance patient care and improve clinical outcomes in healthcare settings.

Products and Services
  • USCOM 1A: A Doppler ultrasound device for assessing cardiovascular performance
  • BP+: A central blood pressure monitor using supra-systolic oscillometry
  • SpiroSonic AIR: A digital spirometer with an integrated viral disinfection system
Growth Outlook
  • Recent quarterly revenue of AUD 502,000 shows potential for recovery
  • Expansion of product offerings aims to capture a larger market share
  • Strategic partnerships with healthcare facilities enhance distribution capabilities
Financial Highlights
  • Trailing twelve months (TTM) revenue of AUD 2.55 million indicates growth potential
  • Net income for the latest quarter was AUD 821,243, a positive shift
  • Current ratio of 1.66 suggests strong short-term financial health
Uscom Limited operates in the medical devices sector, focusing on innovative solutions that address critical healthcare needs. The company's product portfolio includes advanced devices that utilize cutting-edge technology to provide non-invasive assessments of cardiovascular and pulmonary health. With a commitment to improving patient outcomes, Uscom is well-positioned to capitalize on the growing demand for effective medical devices. The growth outlook for Uscom is promising, as evidenced by recent revenue trends and strategic initiatives aimed at expanding its market presence. The latest quarterly results reflect a significant increase in net income, indicating a potential turnaround in financial performance. Additionally, the company's strong current ratio suggests it is well-equipped to meet its short-term obligations, further enhancing investor confidence. Overall, Uscom Limited presents an intriguing opportunity for investors interested in the healthcare sector, particularly in innovative medical technologies that address critical health challenges.
AI Generated • Aug 28, 2026

Industry

Healthcare Equipment and Supplies

CEO

Robert Allan Phillips, PhD

Headquarters

Sydney, NSW 2000, AU

UCM Financials

Key Financial Metrics (TTM)

Gross Margin

8.56%

Operating Margin

-287.91%

Net Income Margin

-105.85%

Return on Equity

-1788.57%

Return on Capital

-167.57%

Return on Assets

-280.53%

Earnings Yield

-44.25%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

A$3.12MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

260.15M

Volume

0

Avg. Volume

0

Financials (TTM)

Gross Profit

A$3.14M

Operating Income

-A$6.21M

EBITDA

-A$4.90M

Operating Cash Flow

-A$4.32M

Capital Expenditure

-A$20.02K

Free Cash Flow

-A$4.34M

Cash & ST Invst.

A$1.87K

Total Debt

A$21.09K

Uscom Performance Analysis

Uscom annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-06-30AUD 2,509,683N/A
20232023-06-30AUD 2,664,1666.2%
20242024-06-30AUD 3,726,84539.9%
20252025-06-30AUD 2,578,793-30.8%
Uscom sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-06-303.7%
Q22024-12-314.9%
Q42025-06-30-61.3%
Q22025-12-31-30.2%
Uscom annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-06-30AUD -0.01N/A
20232023-06-30AUD -0.0230.4%
20242024-06-30AUD -0.01-21.3%
20252025-06-30AUD -0.0253.4%
Uscom sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-06-30-42.6%
Q22024-12-31-4.5%
Q42025-06-30-55.7%
Q22025-12-31129.4%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

A$502.00K

-70.6%

Gross Profit

-A$500.06K

-186.9%

Gross Margin

-99.61%

N/A

Market Cap

A$3.12MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

A$89.19K

N/A

Employees

35

N/A

Net Income

A$821.24K

+191.2%

EBITDA

-A$809.46K

-25.9%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

A$1.87K

-99.9%

Total Debt

A$21.09K

-99.3%

Accounts Receivable

A$459.02K

-37.6%

Inventory

A$0.00

-100.0%

Long Term Debt

A$0.00

-100.0%

Short Term Debt

A$21.09K

-99.1%

Return on Assets

-2.81%

N/A

Return on Invested Capital

-19.24%

N/A

Free Cash Flow

-A$1.29M

-47.5%

Operating Cash Flow

-A$1.29M

-52.3%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
AMT.AXAllegra Medical Technologies Limited
A$0.03+0.00%
RGS.AXRegeneus Ltd
A$0.01+33.33%
VTI.AXVisioneering Technologies, Inc.
A$0.07+0.00%
UBI.AXUniversal Biosensors, Inc.
A$0.01+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
SOXSDirexion Shares ETF Trust - Direxion Daily Semiconductor Bear 3x ETF
$46.34-0.10%
NOKNokia
$10.03+0.03%
SOXLDirexion Shares ETF Trust - Direxion Daily Semiconductor Bull 3x ETF
$117.28+0.10%
INTCIntel
$95.80+0.05%

Questions About UCM

What is the current price of Uscom?

Uscom is trading at A$0.01 per share.

What is the 52-week range for Uscom?

Over the past 52 weeks, Uscom has traded between A$0.01 and A$0.01.

How much debt does Uscom have?

As of the most recent reporting period, Uscom reported total debt of A$2.26M.

How much cash does Uscom have on hand?

Uscom reported A$966.66K in cash and cash equivalents in its most recent financial results.

What is Uscom’s dividend yield?

Uscom does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.